查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1835327

流感診斷市場（按技術和最終用戶分類）—2025-2032 年全球預測

Influenza Diagnostics Market by Technology, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年流感診斷市場規模將成長至 28.6 億美元，複合年成長率為 10.15%。

主要市場統計數據
基準年2024年 13.2億美元
預計2025年 14.5億美元
預測年份：2032年 28.6億美元
複合年成長率（%） 10.15%

臨床、技術和營運促進因素的策略方向，將改變整個醫療保健環境中的流感診斷

流感診斷領域正在加速演變，這得益於日益成長的防範需求、日益成熟的技術以及臨床工作流程的系統級轉變。診斷需求正從季節性偶發性檢測擴展到多重呼吸道檢測、疫情高峰期的即時篩檢以及對易感人群的治療後監測。同時，實驗室整合和檢測分散化正在重塑診斷服務的提供和使用方式。

臨床相關人員越來越重視速度、分析效能和操作簡便性，而醫療保健系統則強調吞吐量、供應彈性和成本效益。這些相互交織的優先事項使得診斷產品開發人員和行銷人員必須將產品設計與實際用例（包括醫院實驗室、門診診所、學術中心和高容量診斷實驗室）相結合，這已成為一項戰略要務。此外，監管透明度和報銷途徑仍然是推動產品採用的關鍵因素，因此必須主動將產品開發時間表與政策預期相協調。

在此背景下，本報告整合了臨床促進因素、技術準備、供應鏈考量和相關人員獎勵，旨在為短期商業策略和長期投資決策提供參考。報告旨在為臨床負責人、研發團隊和商業負責人提供一個可行的框架，幫助他們應對複雜的臨床需求、績效權衡和營運限制。

技術創新、監管演變和營運彈性如何共同重新定義流感診斷的提供地點、方式和人員。

近年來，流感診斷領域發生了重大變化。分子檢測方法的加速應用推動了對即時診斷 (POC) 解決方案的需求，改變了集中式和分散式檢測模式之間的平衡。等溫擴增和整合試劑盒平台的創新為傳統 PCR 工作流程提供了強大的替代方案，在許多用例中實現了快速、更貼近患者的診斷，且不影響分析靈敏度。同時，多重檢測技術的改進使得同時檢測多種呼吸道病原體成為可能，從而擴展了臨床效用。

這些技術進步與營運模式的轉變相伴而生。衛生系統正在投資靈活的檢測能力，以應對季節性激增和意外疫情；實驗室則優先考慮工作流程自動化和數位化整合，以提高通量和數據連接性。供應鏈彈性已成為重中之重，負責人採取多樣化的籌資策略，並盡可能尋求本地生產。此外，全球監管機構正在完善緊急使用和加速核准流程，為能夠證明臨床價值和營運適用性的創新診斷方法提供了機會。

這些轉變並非僅僅是漸進式的；它們改變了檢測的地點、檢測的執行者以及檢測結果對患者預後的影響。因此，策略參與者必須預見日益成熟的技術、不斷發展的法規和買家預期的交匯，才能保持競爭力和臨床相關性。

評估關稅主導的貿易變化對診斷價值鏈中的供應鏈、籌資策略和採購偏好的多方面影響

徵收關稅和貿易措施可能會對整個診斷生態系統產生連鎖反應，影響零件成本、供應鏈設計和商業策略。關稅相關的成本壓力可能會推高進口試劑、耗材和儀器零件的國內價格，促使製造商重新評估其全球籌資策略，遷移敏感的生產業務，並協商簽訂長期供應協議。為此，一些公司正在加快努力實現供應商多元化，並尋找既能保持性能又能降低貿易中斷風險的替代材料。

除了直接的成本影響外，關稅還會改變國產產品與進口產品的相對吸引力，進而影響競爭動態。對於在全球營運的診斷公司而言，關稅可能會促使它們調整分銷佈局和定價策略，以在保持市場進入的同時保護淨利率。面臨採購限制的衛生系統和實驗室可能會更加重視供應彈性和供應商風險管理，從而影響採購合約和首選供應商名單。

監管和採購環境也將隨之調整。除了關稅之外，政策制定者還可能實施獎勵，以提升國內生產能力，加速國產診斷產品的監管審查，並採取策略性儲備措施。因此，能夠展示本地生產能力、強大供應鏈和合規性的公司將獲得策略優勢。最終，應對關稅環境需要製定一個綜合的跨職能計劃，協調採購、製造、監管和商業團隊，以保持產品供應並保障臨床的連續性。

詳細的細分分析揭示了技術模式和最終用戶管道如何決定產品規格、採用趨勢和商業性方法

流感診斷細分涵蓋技術模式和最終用戶管道，每種模式和管道都有不同的效能預期和營運限制。在技​​術路徑內，分子診斷包括傳統的聚合酵素鏈鎖反應方法、等溫擴增技術和即時PCR平台。傳統 PCR 繼續用於優先考慮通量和全面驗證的參考實驗室，而等溫擴增方法（恒溫環型核酸擴增和基於核酸序列的擴增）由於其簡單性和適用於分散式檢查而越來越受歡迎。即時PCR具有支援多重和單重的配置，仍然是高靈敏度應用和確認工作流程的核心。快速診斷包括基於墨盒的平台，該平台整合了用於近患者使用的樣品處理和檢測以及橫向流動化驗，可提供快速、低成本的篩檢選項。血清學診斷包括酵素結合免疫吸附試驗、血凝抑制試驗和中和試驗，這些對於免疫狀態​​評估、疫苗評估和流行病學監測至關重要。

從最終用戶的觀點，學術和研究機構尋求支援方法開發和複雜面板的靈活平台，而診所則尋求能夠提供快速可操作結果的緊湊、易於使用的解決方案。診斷實驗室優先考慮吞吐量、自動化和數據互通性，而醫院則尋求與實驗室資訊系統整合並支援住院護理途徑的可擴展解決方案。技術選擇和最終用戶需求之間的相互作用推動了產品規格、商業性包裝和支援模型。例如，多重即時PCR解決方案非常適合分析深度和吞吐量至關重要的標準實驗室和大型醫院，而等溫和基於墨盒的系統更適合門診診所和分散式檢查設施。認知到這種一致性使供應商能夠調整打入市場策略，確定監管環境的優先級，並設計符合臨床營運現實的服務產品。

區域醫療保健基礎設施、法規環境和製造地如何影響不同的診斷採用模式和策略重點

流感診斷的區域動態反映了美洲、歐洲、中東和非洲以及亞太地區醫療保健基礎設施、管理體制和供應鏈架構的差異。在美洲，成熟的實驗室網路和強大的報銷框架正在推動對高效能分子檢測和整合實驗室解決方案的需求。在歐洲、中東和非洲，協調監管環境和不同醫療保健系統能力的努力正在創造一種異質格局，其中集中式實驗室與不斷增加的分散式檢查投資並存，以改善醫療服務的可及性，尤其是在偏遠和資源匱乏的地區。在該地區，採購慣例和公共衛生監測重點正在影響產品的選擇和分銷模式。

在亞太地區，製造能力、政府主導的檢測計劃以及新平台的快速應用，使該地區成為診斷組件和檢測試劑的主要消費地和關鍵生產中心。本地製造商正在擴大其分子和快速診斷製造能力，以增強該地區供應鏈的韌性，並支援針對大批量檢測環境的客製化解決方案。這些地區差異影響著監管策略、經銷夥伴以及臨床檢驗工作的在地化。因此，尋求區域擴張的公司必須根據每個地區獨特的期望和基礎設施現狀，調整其監管提交、本地支援模式和供應物流。

平台整合、策略夥伴關係和本地生產的競爭動態將決定差異化和長期採購關係

流感診斷領域的競爭格局以成熟的診斷製造商、專業的分子創新者以及不斷擴張的試劑盒和即時診斷平台開發商網路為特徵。產業領導者持續整合其平台，擴展其檢測菜單，並投資於全球分銷，利用其規模優勢來支援服務模式、品質保證和法規申報。同時，敏捷的科技公司正在推動恆溫方法、實驗室晶片整合和增強型快速抗原檢測能力等創新，並經常與臨床實驗室和研究機構合作，以檢驗新的應用。

設備供應商和檢測開發商之間的策略夥伴關係正變得日益重要，這有助於快速將新型檢測引入臨床，並建立連接硬體、耗材和數位服務的生態系統。同時，契約製造和本地生產基地已成為供應保障策略的關鍵組成部分，尤其是在貿易措施和物流中斷限制跨境流動的情況下。那些能夠展現出強大的資料包品質、響應迅速的技術支援和靈活商業模式的公司，很可能在贏得與醫療系統和大型實驗室網路的多年期採購合約方面佔據有利地位。鑑於這些動態，產業相關人員必須在產品創新與臨床客戶所需的營運嚴謹性之間取得平衡。

相關人員可採取的優先事項包括加強供應彈性、使產品設計與臨床工作流程保持一致以及透過策略夥伴關係加速採用

產業領導者可以採取積極主動的措施，增強韌性，加速產品採用，並獲得臨床價值。首先，將產品開發與優先的臨床工作流程（例如，快速門診排除或住院患者管理的多重檢測組合）相結合，以確保產品性能特徵轉化為臨床醫生的實際利益。其次，投資於供應鏈多元化和區域製造能力，以減少貿易中斷帶來的風險，並在需求激增期間支援更快的交付時間。第三，與實驗室網路、衛生系統和學術中心建立策略合作夥伴關係，以加速現實世界的檢驗，並與大型採購商建立信任。

此外，公司必須將監管策略作為競爭優勢，協調證據產生以支持目標全部區域的核准途徑，並預測監管預期的變化。商業性角度來看，彈性價格設定和服務模式能夠反映付款方的限制和採購週期，從而實現更廣泛的應用，尤其是在分散的環境中。最後，將數位連接和數據分析融入產品中，可以透過實現品管、遠端故障排除以及與電子健康記錄的整合來提升客戶價值。透過執行這些必要措施，領導者可以將技術優勢轉化為持續的臨床和商業性成果。

我們的證據主導方法結合了主要相關人員訪談、監管和技術文件審查以及跨源三角測量，以確保嚴謹且可操作的調查結果

本研究結合了臨床實驗室主任、採購人員和產品開發主管的初步訪談，以及對監管指南、同行評審文獻以及儀器和檢測試劑供應商的檢驗技術規範的二次研究。調查方法和資料來源經過三角檢驗，以確保研究的穩健性。定性洞察為技術採用敘述提供訊息，而技術文件則構成了性能表徵和互通性考慮的基礎。

在現場訪問期間，我們進行了結構化對話，以了解醫院、診斷實驗室、診所和學術中心的營運限制、採購標準和臨床決策促進因素。這些洞察與監管文件和產品技術手冊進行了交叉比對，以確認聲稱的功能與實際營運的一致性。分析框架優先考慮技術準備、整合複雜性和供應鏈相關人員尋求在本地檢驗特定要素的利害關係人提供了可複製性。

總結性結論強調，技術創新、營運彈性和策略協調是診斷領域持久成功的先決條件

不斷發展的流感診斷環境既充滿複雜性，也蘊含著機會。分子檢測和快速檢測技術的進步，以及醫療保健的日益分散化和供應鏈審查的加強，正在重新定義臨床客戶的價值驅動力。同時，地緣政治和貿易發展凸顯了靈活採購和區域製造策略的必要性。產業參與者的成功將取決於他們能否將技術創新與卓越營運相結合，滿足不同司法管轄區的監管要求，並透過真實世界檢驗證明其切實的臨床有效性。

清晰的策略根植於對終端使用者工作流程、區域基礎設施和競爭定位的理解，使企業能夠優先考慮能夠帶來差異化價值的投資。可靠的供應，加上以客戶為中心的服務模式、監管準備以及有針對性的夥伴關係關係，使主導能夠在穩定和快速成長的需求環境中保持領先地位。最終，基於嚴謹證據的明智行動以及與臨床相關人員的密切合作，將決定誰能抓住流感診斷領域最持久的商機。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 快速分子就地檢驗的擴展將允許在幾分鐘內檢測到患者附近的流感。
  • 開發整合甲型/乙型流感及其他病毒和細菌標靶的多重呼吸道檢測組
  • 採用基於 CRISPR 的診斷檢測方法對流感病毒株進行靈敏檢測
  • 整合數位健康平台，用於遠端監控和報告流感檢測結果
  • 家用流感檢測自採集套件的出現，並配有遠端醫療醫療指導解讀
  • 利用次世代定序進行全面的流感病毒監測和突變追蹤
  • 傳播基於生物標記的預後測試，針對重症流感患者的標靶治療
  • 擴大使用人工智慧分析來預測流感爆發並最佳化診斷資源分配

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第8章流感診斷市場（按技術）

  • 分子診斷
    • 常規PCR
    • 等溫擴增
      • 環介導等溫擴增
      • 基於核酸序列的擴增
    • 即時PCR
      • 多重PCR套件
      • 單重PCR套件
  • 快速診斷
    • 基於墨盒的平台
    • 橫向流動化驗
  • 血清學診斷
    • 伊麗莎
    • 抑制紅血球聚集
    • 中和試驗

第9章 流感診斷市場（依最終用戶）

  • 學術研究機構
  • 診所
  • 診斷實驗室
  • 醫院

第 10 章流感診斷市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第11章流感診斷市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第12章 流感診斷市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第13章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • F. Hoffmann-La Roche Ltd.
    • Abbott Laboratories
    • Quidel Corporation
    • Becton, Dickinson and Company
    • Thermo Fisher Scientific Inc.
    • bioMerieux SA
    • Hologic, Inc.
    • Luminex Corporation
    • Meridian Bioscience, Inc.
Product Code: MRR-43127F72796F

The Influenza Diagnostics Market is projected to grow by USD 2.86 billion at a CAGR of 10.15% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.32 billion
Estimated Year [2025] USD 1.45 billion
Forecast Year [2032] USD 2.86 billion
CAGR (%) 10.15%

A strategic orientation to the changing clinical, technological, and operational drivers reshaping influenza diagnostics across healthcare delivery settings

The landscape of influenza diagnostics is undergoing a period of accelerated evolution driven by heightened preparedness demands, technological maturation, and system-level shifts in clinical workflows. Diagnostic needs have expanded beyond episodic seasonal testing to encompass multiplexed respiratory panels, point-of-care screening during surge events, and post-therapeutic monitoring for vulnerable populations. Concurrently, laboratory consolidation and the push for decentralized testing have reshaped how diagnostic services are delivered and consumed.

Clinical stakeholders increasingly prioritize speed, analytical performance, and operational simplicity, while health systems emphasize throughput, supply resilience, and cost-effectiveness. These intersecting priorities create a strategic imperative for diagnostics developers and distributors to align product design with real-world use cases across hospital laboratories, outpatient clinics, academic centers, and high-volume diagnostic laboratories. Moreover, regulatory clarity and reimbursement pathways remain decisive factors for adoption, necessitating proactive alignment between product development timelines and policy expectations.

In this context, the report synthesizes clinical drivers, technology readiness, supply chain considerations, and stakeholder incentives into a cohesive view that informs near-term commercial strategy and longer-term investment decisions. The intent is to provide an actionable framework that supports clinical leaders, R&D teams, and commercial strategists as they navigate the complex matrix of clinical need, performance trade-offs, and operational constraints.

How technological innovation, regulatory evolution, and operational resilience are collectively redefining where, how, and by whom influenza diagnostics are delivered

Recent years have seen transformative shifts in the influenza diagnostics landscape characterized by accelerated adoption of molecular testing modalities, greater demand for point-of-care solutions, and a rebalancing of centralized versus decentralized testing models. Innovations in isothermal amplification and integrated cartridge platforms have delivered robust alternatives to traditional PCR workflows, enabling rapid, near-patient diagnostics without compromising analytical sensitivity in many use cases. At the same time, improvements in assay multiplexing have expanded clinical utility by enabling simultaneous detection of multiple respiratory pathogens, which supports more informed clinical decision-making.

Parallel to these technological advances, operational shifts have emerged. Health systems have invested in flexible testing capacity to respond to seasonal surges and unexpected outbreaks, while laboratories have prioritized workflow automation and digital integration to improve throughput and data connectivity. Supply chain resiliency has become a top-tier imperative, prompting suppliers and purchasers to diversify sourcing strategies and to pursue regional manufacturing wherever feasible. Additionally, regulatory agencies globally have refined pathways for emergency use and accelerated approvals, creating windows of opportunity for innovative diagnostics that can demonstrate clinical value and operational fit.

Taken together, these shifts are not merely incremental; they change where testing occurs, who performs it, and how outcomes influence patient pathways. Strategic actors must therefore anticipate the confluence of technology maturation, regulatory evolution, and purchaser expectations to remain competitive and clinically relevant.

Assessing the multifaceted consequences of tariff-driven trade changes on supply chains, sourcing strategies, and procurement preferences within the diagnostics value chain

The introduction of tariffs and trade measures can have cascading effects across the diagnostics ecosystem, influencing component costs, supply chain design, and commercial strategy. Tariff-related cost pressures can raise the landed cost of imported reagents, disposables, and instrument components, thereby incentivizing manufacturers to reassess global sourcing strategies, relocate sensitive production steps, or negotiate longer-term supply contracts. In response, some firms accelerate efforts to diversify suppliers and to qualify alternative materials that preserve performance while mitigating exposure to trade disruptions.

In addition to direct cost implications, tariffs can influence competitive dynamics by altering the relative attractiveness of domestically manufactured versus imported products. For diagnostic companies with global footprints, tariff regimes can prompt restructuring of distribution footprints and pricing strategies to maintain market access while protecting margins. Health systems and laboratories, facing procurement constraints, may place higher value on supply resilience and vendor risk management, which influences procurement contracting and preferred supplier lists.

Regulatory and procurement environments also adapt. Policymakers may complement tariff actions with incentives for local manufacturing capacity, expedited regulatory reviews for domestically produced diagnostics, or strategic stockpiling initiatives. As a result, firms that can demonstrate local production capabilities, robust supply chains, and regulatory compliance gain a strategic advantage. Ultimately, navigating the tariff environment requires integrated cross-functional planning that aligns sourcing, manufacturing, regulatory, and commercial teams to sustain product availability and protect clinical continuity.

Detailed segmentation analysis illuminating how technology modalities and end-user channels dictate product specifications, adoption dynamics, and commercial approaches

Segmentation in influenza diagnostics spans technology modalities and end-user channels, each with distinct performance expectations and operational constraints. Within technology pathways, molecular diagnostics include conventional polymerase chain reaction approaches, isothermal amplification techniques, and real-time PCR platforms. Conventional PCR continues to serve reference laboratories where throughput and comprehensive validation are priorities, while isothermal amplification-comprising methods such as loop-mediated isothermal amplification and nucleic acid sequence-based amplification-has gained traction for its simplicity and suitability for decentralized testing. Real-time PCR, with configurations that support both multiplexing and singleplex formats, remains central to high-sensitivity applications and confirmatory workflows. Rapid diagnostics encompass cartridge-based platforms that integrate sample processing and detection for near-patient use, as well as lateral flow assays that provide quick, low-cost screening options. Serological diagnostics cover enzyme-linked immunosorbent assays, hemagglutination inhibition assays, and neutralization tests, which are critical for immune status assessment, vaccine evaluation, and epidemiologic surveillance.

From an end-user perspective, academic and research institutes seek flexible platforms that support method development and complex panels, while clinics require compact, easy-to-use solutions that deliver rapid actionable results. Diagnostic laboratories prioritize throughput, automation, and data interoperability, and hospitals demand scalable solutions that integrate with laboratory information systems and support inpatient care pathways. The interplay between technology choice and end-user requirements drives product specification, commercial packaging, and support models. For example, multiplex real-time PCR solutions are well aligned to reference laboratories and large hospitals where analytical depth and throughput are essential, whereas isothermal and cartridge-based systems better serve outpatient clinics and decentralized testing sites. Recognizing these alignments enables suppliers to tailor go-to-market strategies, prioritize regulatory submissions, and design service offerings that match operational realities across the clinical landscape.

How regional healthcare infrastructures, regulatory environments, and manufacturing footprints shape divergent adoption patterns and strategic priorities for diagnostics

Regional dynamics in influenza diagnostics reflect differences in healthcare infrastructure, regulatory regimes, and supply chain architectures across the Americas, Europe, Middle East and Africa, and Asia-Pacific. In the Americas, established laboratory networks and strong reimbursement frameworks drive demand for high-performance molecular assays and integrated laboratory solutions, while pockets of innovation have accelerated the adoption of point-of-care testing in community settings. Across Europe, the Middle East and Africa, regulatory harmonization efforts and variable health system capacities create a heterogeneous landscape in which centralized laboratories coexist with growing investments in decentralized testing to improve access, particularly in remote or resource-constrained areas. Procurement practices and public health surveillance priorities influence product selection and distribution models in this region.

In the Asia-Pacific, a combination of manufacturing capacity, government-led testing initiatives, and rapid uptake of novel platforms has positioned the region as both a major consumer and an important production hub for diagnostic components and assays. Local manufacturers have expanded capabilities across molecular and rapid diagnostics, supporting regional supply chain resilience and enabling tailored solutions for high-volume testing environments. These regional distinctions have implications for regulatory strategy, distribution partnerships, and localization of clinical validation efforts. Consequently, firms seeking regional scale must adapt regulatory submissions, local support models, and supply logistics to the distinct expectations and infrastructure realities of each geography.

Competitive dynamics driven by platform integration, strategic partnerships, and localized production that determine differentiation and long-term procurement relationships

The competitive field in influenza diagnostics is characterized by a mix of established diagnostics manufacturers, specialized molecular innovators, and an expanding set of cartridge and point-of-care platform developers. Large industry players continue to invest in platform integration, expanded assay menus, and global distribution networks, leveraging scale to support service models, quality assurance, and regulatory submissions. At the same time, agile technology companies drive innovation in isothermal methods, lab-on-a-chip integration, and rapid antigen detection enhancements, often partnering with clinical laboratories and research institutions to validate new applications.

Strategic partnerships between instrument providers and assay developers are increasingly important, enabling faster time-to-clinic for novel tests and creating ecosystems that link hardware, consumables, and digital services. In parallel, contract manufacturers and localized production sites have become key components of supply assurance strategies, particularly when trade measures or logistics disruptions constrain cross-border flows. Companies that demonstrate a combination of robust data package quality, responsive technical support, and flexible commercial models will be better positioned to win multi-year procurement agreements with health systems and large laboratory networks. Observing these dynamics, industry participants must balance product innovation with the operational rigor required by clinical customers.

Actionable priority initiatives for stakeholders to fortify supply resilience, align product design with clinical workflows, and accelerate adoption through strategic partnerships

Industry leaders can take proactive steps to strengthen resilience, accelerate adoption, and capture clinical value. First, aligning product development with prioritized clinical workflows-such as rapid rule-out in outpatient settings and multiplexed panels for inpatient management-ensures that performance features translate into actionable benefits for clinicians. Second, investing in supply chain diversification and regional manufacturing capacity reduces exposure to trade disruptions and supports faster delivery times during demand surges. Third, pursuing strategic alliances with laboratory networks, health systems, and academic centers accelerates real-world validation and builds credibility with large purchasers.

In addition, companies should prioritize regulatory strategy as a competitive asset, coordinating evidence generation to support approval pathways across target regions and anticipating changes in regulatory expectations. Commercially, flexible pricing and service models that reflect payer constraints and procurement cycles can unlock broader adoption, especially in decentralized settings. Finally, embedding digital connectivity and data analytics into product offerings enhances customer value by enabling quality control, remote troubleshooting, and integration with electronic health records. By executing on these imperatives, leaders can convert technical advantage into durable clinical and commercial outcomes.

An evidence-driven methodology combining primary stakeholder interviews, regulatory and technical documentation review, and cross-source triangulation to ensure rigorous and actionable findings

This research synthesizes primary interviews with clinical laboratory directors, procurement leads, and product development executives, combined with secondary analysis of regulatory guidance, peer-reviewed literature, and validated technical specifications from instrument and assay providers. The methodological approach emphasizes triangulation across data sources to ensure robustness: qualitative insights inform technology adoption narratives, while technical documentation underpins performance characterizations and interoperability considerations.

Field engagement included structured conversations to surface operational constraints, procurement criteria, and clinical decision drivers across hospitals, diagnostic laboratories, clinics, and academic centers. These insights were cross-referenced with regulatory filings and product technical manuals to ensure alignment between claimed capabilities and operational realities. Analytical frameworks prioritized technology readiness, integration complexity, and supply chain dependencies to produce strategic recommendations that are practical and evidence-based. Transparency in assumptions and clear documentation of data sources underpin the credibility of the findings and support reproducibility for stakeholders seeking to validate specific elements locally.

Concluding synthesis emphasizing the intersection of technological innovation, operational resilience, and strategic alignment as prerequisites for durable success in diagnostics

The evolving influenza diagnostics environment presents both complexity and opportunity. Technological advances in molecular and rapid testing, combined with shifts toward decentralized care and heightened supply chain scrutiny, are redefining value drivers for clinical customers. At the same time, geopolitical and trade developments underscore the need for flexible sourcing and regional manufacturing strategies. For industry participants, success will depend on the ability to integrate technical innovation with operational excellence, to navigate regulatory expectations across jurisdictions, and to demonstrate tangible clinical impact through real-world validations.

Strategic clarity-rooted in an understanding of end-user workflows, regional infrastructure, and competitive positioning-enables organizations to prioritize investments that deliver differentiated value. Those that couple reliable supply with customer-focused service models, regulatory preparedness, and targeted partnerships will be positioned to lead in both stable and surge-demand environments. Ultimately, informed action based on rigorous evidence and close engagement with clinical stakeholders will determine who captures the most durable opportunities in the influenza diagnostics arena.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of rapid molecular point-of-care testing enabling near-patient influenza detection within minutes
  • 5.2. Development of multiplex respiratory panels integrating influenza A/B with other viral and bacterial targets
  • 5.3. Adoption of CRISPR-based diagnostic assays offering high sensitivity detection of influenza strains
  • 5.4. Integration of digital health platforms for remote monitoring and reporting of influenza test results
  • 5.5. Emergence of at-home self-collection kits for influenza testing with telehealth-guided interpretation
  • 5.6. Utilization of next-generation sequencing for comprehensive influenza virus surveillance and mutation tracking
  • 5.7. Growth of biomarker-based prognostic tests differentiating severe influenza cases for targeted therapy
  • 5.8. Increasing use of AI-driven analytics to predict influenza outbreaks and optimize diagnostic resource allocation

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Influenza Diagnostics Market, by Technology

  • 8.1. Molecular Diagnostics
    • 8.1.1. Conventional PCR
    • 8.1.2. Isothermal Amplification
      • 8.1.2.1. Loop Mediated Isothermal Amplification
      • 8.1.2.2. Nucleic Acid Sequence Based Amplification
    • 8.1.3. Real Time PCR
      • 8.1.3.1. Multiplex PCR Kits
      • 8.1.3.2. Singleplex PCR Kits
  • 8.2. Rapid Diagnostics
    • 8.2.1. Cartridge Based Platforms
    • 8.2.2. Lateral Flow Assay
  • 8.3. Serological Diagnostics
    • 8.3.1. Elisa
    • 8.3.2. Hemagglutination Inhibition
    • 8.3.3. Neutralization Test

9. Influenza Diagnostics Market, by End User

  • 9.1. Academic & Research Institutes
  • 9.2. Clinics
  • 9.3. Diagnostic Laboratories
  • 9.4. Hospitals

10. Influenza Diagnostics Market, by Region

  • 10.1. Americas
    • 10.1.1. North America
    • 10.1.2. Latin America
  • 10.2. Europe, Middle East & Africa
    • 10.2.1. Europe
    • 10.2.2. Middle East
    • 10.2.3. Africa
  • 10.3. Asia-Pacific

11. Influenza Diagnostics Market, by Group

  • 11.1. ASEAN
  • 11.2. GCC
  • 11.3. European Union
  • 11.4. BRICS
  • 11.5. G7
  • 11.6. NATO

12. Influenza Diagnostics Market, by Country

  • 12.1. United States
  • 12.2. Canada
  • 12.3. Mexico
  • 12.4. Brazil
  • 12.5. United Kingdom
  • 12.6. Germany
  • 12.7. France
  • 12.8. Russia
  • 12.9. Italy
  • 12.10. Spain
  • 12.11. China
  • 12.12. India
  • 12.13. Japan
  • 12.14. Australia
  • 12.15. South Korea

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2024
  • 13.2. FPNV Positioning Matrix, 2024
  • 13.3. Competitive Analysis
    • 13.3.1. F. Hoffmann-La Roche Ltd.
    • 13.3.2. Abbott Laboratories
    • 13.3.3. Quidel Corporation
    • 13.3.4. Becton, Dickinson and Company
    • 13.3.5. Thermo Fisher Scientific Inc.
    • 13.3.6. bioMerieux SA
    • 13.3.7. Hologic, Inc.
    • 13.3.8. Luminex Corporation
    • 13.3.9. Meridian Bioscience, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 7. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. BRICS INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. G7 INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. NATO INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. INFLUENZA DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 24. INFLUENZA DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. INFLUENZA DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY CONVENTIONAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY CONVENTIONAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY CONVENTIONAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY CONVENTIONAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY CONVENTIONAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY CONVENTIONAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID SEQUENCE BASED AMPLIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID SEQUENCE BASED AMPLIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID SEQUENCE BASED AMPLIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID SEQUENCE BASED AMPLIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID SEQUENCE BASED AMPLIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID SEQUENCE BASED AMPLIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY MULTIPLEX PCR KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY MULTIPLEX PCR KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY MULTIPLEX PCR KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY MULTIPLEX PCR KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY MULTIPLEX PCR KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY MULTIPLEX PCR KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY SINGLEPLEX PCR KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY SINGLEPLEX PCR KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY SINGLEPLEX PCR KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY SINGLEPLEX PCR KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY SINGLEPLEX PCR KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY SINGLEPLEX PCR KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY CARTRIDGE BASED PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY CARTRIDGE BASED PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY CARTRIDGE BASED PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY CARTRIDGE BASED PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY CARTRIDGE BASED PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY CARTRIDGE BASED PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY HEMAGGLUTINATION INHIBITION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY HEMAGGLUTINATION INHIBITION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY HEMAGGLUTINATION INHIBITION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY HEMAGGLUTINATION INHIBITION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY HEMAGGLUTINATION INHIBITION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY HEMAGGLUTINATION INHIBITION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY NEUTRALIZATION TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY NEUTRALIZATION TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY NEUTRALIZATION TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY NEUTRALIZATION TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY NEUTRALIZATION TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY NEUTRALIZATION TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 137. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 139. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 141. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2024 (USD MILLION)
  • TABLE 142. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 154. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 156. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2024 (USD MILLION)
  • TABLE 158. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2025-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2024 (USD MILLION)
  • TABLE 160. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2025-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 162. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 170. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 172. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2025-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2024 (USD MILLION)
  • TABLE 176. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2025-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 178. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 218. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 220. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2024 (USD MILLION)
  • TABLE 222. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2025-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2024 (USD MILLION)
  • TABLE 224. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2025-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 226. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 228. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 231. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 234. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 235. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 236. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 237. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2024 (USD MILLION)
  • TABLE 238. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2025-2032 (USD MILLION)
  • TABLE 239. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2024 (USD MILLION)
  • TABLE 240. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2025-2032 (USD MILLION)
  • TABLE 241. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 242. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 243. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 244. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 245. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2024 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2025-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2024 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2025-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 268. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 269. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 270. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 271. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2024 (USD MILLION)
  • TABLE 272. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2025-2032 (USD MILLION)
  • TABLE 273. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2024 (USD MILLION)
  • TABLE 274. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2025-2032 (USD MILLION)
  • TABLE 275. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 276. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 277. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 278. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 279. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 280. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 281. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 284. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 285. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 286. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 287. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2024 (USD MILLION)
  • TABLE 288. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2025-2032 (USD MILLION)
  • TABLE 289. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2024 (USD MILLION)
  • TABLE 290. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2025-2032 (USD MILLION)
  • TABLE 291. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 292. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 293. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 294. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 295. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 296. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGICAL DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 312. E